Alkermes to Report First Quarter Financial Results on May 1, 2025

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has announced it will host a conference call and webcast presentation on Thursday, May 1, 2025, at 8:00 a.m. ET to discuss its first quarter financial results.

The presentation will be accessible through the Investors section of Alkermes' website, with dial-in options available for U.S. callers (+1 877 407 2988) and international callers (+1 201 389 0923). A replay will be available approximately two hours after the event.

Alkermes specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, with ongoing research in neurological disorders including narcolepsy and idiopathic hypersomnia. The company maintains operations across Ireland, Massachusetts, and Ohio.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, ALKS declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc  
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations 
+1 781 873 2402

 

View original content:https://www.prnewswire.com/news-releases/alkermes-to-report-first-quarter-financial-results-on-may-1-2025-302431565.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) release Q1 2025 earnings?

Alkermes will release its Q1 2025 earnings on Thursday, May 1, 2025, at 8:00 a.m. ET (1:00 p.m. BST).

How can investors access ALKS Q1 2025 earnings call?

Investors can access the webcast through Alkermes' website investor section, or dial +1 877 407 2988 (US) or +1 201 389 0923 (international).

What are the main therapeutic areas for Alkermes (ALKS)?

Alkermes focuses on neuroscience, with treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and research in narcolepsy and idiopathic hypersomnia.

Where are Alkermes (ALKS) main operations located?

Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.